Investing.com - Taiwan Liposome ADR reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Taiwan Liposome ADR announced earnings per share of $-0.02 on revenue of $5.7M. Analysts polled by Investing.com anticipated EPS of $-0.1267 on revenue of $976.33K.
Taiwan Liposome ADR shares are up 58.69% from the beginning of the year, still down 24.00% from its 52 week high of $9.25 set on August 14, 2020. They are outperforming the Nasdaq which is up 14.56% from the start of the year.
Taiwan Liposome ADR follows other major Healthcare sector earnings this month
Taiwan Liposome ADR's report follows an earnings beat by Merck ADR on August 5, who reported EPS of $0.5304 on revenue of $5.77B, compared to forecasts EPS of $0.4897 on revenue of $5.63B.
Hoya Corp had beat expectations on July 29 with second quarter EPS of $1.02 on revenue of $1.44B, compared to forecast for EPS of $0.8576 on revenue of $1.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar